Press Releases
Another Evergreen Me-Only Drug Cleared by the FDA for Phase II Clinical Trial
February 10, 2022
On February 4, 2022, Evergreen Therapeutics announced that the IND for an oral drug for the treatment of dry macular degeneration with independent intellectual property rights, EG-301, was cleared by the US FDA to proceed to its phase II clinical trial.
FDA Experts Association Holds Autumn Gathering in Washington DC
October 20, 2021
In celebration of the “Golden Autumn” season, the FDA Experts Association hosted its North America Golden Autumn Reception on October 16, 2021, in North Bethesda, Maryland.
Preclinical studies of EG-301 demonstrate an acceptable safety profile and preliminary in vivo efficacy
April 30, 2021
Evergreen Therapeutics announced that EG-301, an oral small-molecule candidate developed for dry age-related macular degeneration (dry AMD), has demonstrated both an acceptable safety profile and preliminary efficacy in attenuating disease progression in preclinical animal studies.
